Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272760 | 1.00 | TSHR (0.50) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4271847 | 1.00 | TSHR (0.50) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4276810 | 1.00 | TSHR (0.50) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4272681 | 1.00 | TSHR (0.50) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4281510 | 1.00 | TSHR (0.50) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4279309 | 0.98 | TSHR (0.52) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4276664 | 0.98 | TSHR (0.46) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4271837 | 0.98 | TSHR (0.46) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4272620 | 0.98 | TSHR (0.46) | TSHRSMN1; SMN2DNM1LMNAADH1B | |
| SCHEMBL4268918 | 0.98 | TSHR (0.46) | TSHRSMN1; SMN2DNM1LMNAADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10230023-B2 | Color converter | BASF SE (DE) | 2019-03-12 | — | — | US | disclosed |
| EP-2718395-B1 | Novel illumination device comprising a colour converter | BASF SE (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20160284947-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9406848-B2 | Color converter | BASF SE (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2718395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2012-12-13 | — | — | WO | disclosed |
| WO-2009037283-A1 | METHOD FOR PRODUCING SUBSTRATES COATED WITH RYLENE TETRACARBOLIC ACID DIIMIDES | BASF SE (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | BASF SE (DE) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | AXIN2, NCSTN, NES | TSHR 3585/4885SMN1; SMN2 3380/4885DNM1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.